What was the main finding for Beclin-1 as a predictive marker in adjunctively treated tumors?

• A. Low Beclin-1 group had significantly shorter survival
• B. Beclin-1 had no impact on survival
• C. Beclin-1 predicted only disease-free interval
• D. High Beclin-1 expression was associated with significantly shorter survival, with HR values 5.7 and 7.4

Answer: (D)

The main idea here is how a biomarker’s level can predict outcome under a specific treatment. Beclin-1 is an autophagy-related protein, and higher autophagic activity can help tumor cells survive therapy. In tumors treated adjunctively, high Beclin-1 expression was linked to much shorter overall survival. This is quantified by hazard ratios of 5.7 and 7.4, meaning those with high Beclin-1 had a 5–7 fold higher risk of death during the study period compared with those with lower Beclin-1.

So this marker serves as a strong predictor of worse prognosis under adjunctive therapy. The other ideas don’t fit because the data show the danger with high, not low, Beclin-1; the effect is on survival (not only disease-free interval), and there is a measurable impact rather than no impact.